early potent protection against heterologous sivsme660 challenge following live attenuated siv vaccination in mauritian cynomolgus macaques早期有效的防止异种的sivsme660挑战在毛里求斯猕猴猴猴免疫缺陷病毒减毒活疫苗接种后.pdfVIP

Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques 1 1 1 1 1 1 Neil Berry *, Claire Ham , Edward T. Mee , Nicola J. Rose , Giada Mattiuzzo , Adrian Jenkins , Mark 1 1 1 1 1 3 Page , William Elsley , Mark Robinson , Deborah Smith , Deborah Ferguson , Greg Towers , Neil Almond1, Richard Stebbings2 1 Division of Retrovirology, National Institute for Biological Standards and Control (NIBSC), Health Protection Agency (HPA), South Mimms, Potters Bar, Hertfordshire, United Kingdom, 2 Division of Biotherapeutics, NIBSC/HPA, South Mimms, Potters Bar, Hertfordshire, United Kingdom, 3 MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London, United Kingdom Abstract Background: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation. Methodology/Principal Findings: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following vaccination